NCT02207309 2024-08-09
Pazopanib Maintenance Phase II
Ludwig-Maximilians - University of Munich
Phase 2 Terminated
Clinical Trials
21 trialsNCT03334409 2022-03-31
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Terminated
NCT02212015 2022-03-22
EVA
Heidelberg University
Phase 2 Terminated
NCT02959554 2021-09-08
NIVOSWITCH
AIO-Studien-gGmbH
Phase 2 Terminated
NCT01759303 2021-04-13
Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
Emerald Clinical Inc.
Phase 2 Terminated
NCT01543802 2021-01-26
NOPASS
Heidelberg University
Phase 2 Terminated
NCT02193152 2020-07-14
Pazopanib in Molecularly Selected Patients With Advanced NSCLC
Washington University School of Medicine
Phase 2 Terminated
NCT01392352 2020-02-13
HYPAZ
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT01855724 2018-11-07
Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer
Hellenic Cooperative Oncology Group
Phase 2 Terminated
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01394211 2018-07-26
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
University of Arizona
Phase 2 Terminated
NCT02113826 2017-11-06
Pazopanib for Metastatic Alveolar Soft Part Sarcoma
Seoul National University Hospital
Phase 2 Terminated
NCT01340794 2017-09-21
Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01622660 2017-08-22
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT02089802 2017-08-18
OPERA
Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
Phase 2 Terminated
NCT01391611 2017-04-07
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
Stanford University
Phase 2 Terminated
NCT01059656 2016-07-01
DFSP-PAZO
Assistance Publique - Hôpitaux de Paris
Phase 2 Terminated
NCT01080248 2015-06-09
Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT00549328 2014-11-19
Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT01049776 2014-09-19
GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line
Illinois CancerCare, P.C.
Phase 2 Terminated
NCT00945477 2013-11-18
Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
Illinois CancerCare, P.C.
Phase 2 Terminated